Article Data

  • Views 804
  • Dowloads 128

Case Report

Open Access Special Issue

Neuroendocrine cancer of the prostate. Two case reports

  • Tamás Kullmann1
  • Szigeti András1
  • Kránitz Noémi2
  • Szepesváry Zsolt3

1Department of Oncoradiology, Petz Aladár Hospital, 9024 Győr, Hungary

2Department of Pathology, Petz Aladár Hospital, 9024 Győr, Hungary

3Department of Urology, Petz Aladár Hospital, 9024 Győr, Hungary

DOI: 10.31083/j.jomh1803065 Vol.18,Issue 3,March 2022 pp.1-4

Submitted: 31 August 2021 Accepted: 26 October 2021

Published: 31 March 2022

(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)

*Corresponding Author(s): Tamás Kullmann E-mail:


Background: Neuroendocrine cancer of the prostate can present in diverse clinical pictures, potentially hampering the diagnosis and probably leading to underdiagnosis. Methods: Two cases are presented corresponding respectively to two forms of the disease: de novo neuroendocrine cancer and dedifferenciation of an adenocarcinoma of the prostate to neuroendocrine cancer under long term luteinising hormone releasing hormone (LHRH) agonist treatment. Results: Suspicion of neuroendocrine cancer may be raised in prostate cancer patients presenting either clinical or radiological metastatic progression without prostate specific antigen (PSA) rise, or relatively extended metastatic disease right at diagnosis associated to relatively low PSA, yet any non-pulmonary visceral metastases. Neuroendocrine cancer of the prostate can also turn out to be the origin of an adenocarcinoma of unknown primary. Conclusion: In case these considerations are respected the risk of missing the correct diagnosis of a neuroendocrine cancer of the prostate may be minimised.


Neuroendocrine cancer; Prostate cancer; Serum marker; Synaptophysin; NSE

Cite and Share

Tamás Kullmann,Szigeti András,Kránitz Noémi,Szepesváry Zsolt. Neuroendocrine cancer of the prostate. Two case reports. Journal of Men's Health. 2022. 18(3);1-4.


[1] Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah S, Moschini M, et al. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: a SEER Database Analysis. Clinical Genitourinary Cancer. 2017; 15: e793–e800.

[2] Yamada Y, Beltran H. Clinical and Biological Features of Neuroendocrine Prostate Cancer. Current Oncology Reports. 2021; 23: 1–10.

[3] Kránitz N, Szepesváry Z, Kocsis K, Kullmann T. Neuroendocrine Cancer of the Prostate. Pathology and Oncology Research. 2020; 26: 1447–1450.

[4] Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology. 2018; 36: 2492–2503.

[5] Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile rec-ognizes transformation to castration-resistant neuroendocrine prostate cancer. The Journal of Clinical Investigation. 2020; 130: 1653–1668.

[6] Kumar K, Ahmed R, Chukwunonso C, Tariq H, Niazi M, Makker J, et al. Poorly differentiated small-cell-type neuroen-docrine carcinoma of the prostate: a case report and literature review. Case Reports in Oncology. 2018; 11: 676–681.

[7] Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase a In-hibitor Alisertib for Patients with Castration-resistant and Neu-roendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research. 2019; 25: 43–51.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time